Indivior PLC

Report Publication Announcement • Sep 1, 2021

National Storage Mechanism | Additional information

RNS Number : 3850K

Indivior PLC

01 September 2021

Indivior to Participate in Upcoming Investor Conferences

Richmond, VA and Slough, UK (September 1, 2021) - Indivior PLC, (LON: INDV) will participate in the following upcoming virtual investor events:

·    Morgan Stanley 19th Annual Global Healthcare Conference

On Monday, September 13th from 9:30 a.m. to 10:00 a.m. (US EDT) Mark Crossley, Chief Executive Officer (CEO), will participate in a fireside chat event. The live webcast will be available here and at www.indivior.com/investors.

·    BofA Global Healthcare Conference 2021

Mark Crossley, CEO, will host 1x1/Group meetings on Wednesday, September 15th. Please contact your BofA representative to schedule a meeting.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Investor Contact:

Jason Thompson

Vice President, Investor Relations

Indivior PLC (LON: INDV)

Mobile: 804-402-7123

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEANNFELFFEEA